CD8A and lung carcinoma: Similarly, in anti-PD-1-treated lung cancer patients, it was observed that CD8+ CD103+ TILs accumulated in patients with better progression-free survival; these TILs were enriched with TRM-like cells having a unique Tc1/Tc17 effector signature, further emphasizing the distinguished differentiation program of TRM and their critical role in response to ICB (84).